Clinical Analysis of Lacosamide Monotherapy in the Treatment of Self-Limited Epilepsy with Centrotemporal Spikes

References

• Iapadre G, Balagura G, Zagaroli L, et al. Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents. Paediatr Drugs. 2018;20(5):429–453. doi:10.1007/s40272-018-0302-4
   PubMed Web of Science ®Google Scholar
• Xiao-Yan L. Clinical electroencephalography. Beijing. 2017;(335):342. Chinese.
   Google Scholar
• Yang L, Gao L, Luan Y, et al. Different drug treat with central-temporal region spike wave of benign epilepsy in children. J Med Forum. 2017;38(9):21–23.
   Google Scholar
• Coppola G, Franzoni E, Verrotti A, et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev. 2007;29(5):281–284. doi:10.1016/j.braindev.2006.09.008
   Web of Science ®Google Scholar
• Verrotti A, Loiacono G, Coppola G, et al. Pharmacotherapy for children and adolescents with epilepsy. Expert Opin Pharmacother. 2011;12(2):175–194. doi:10.1517/14656566.2010.517194
   PubMed Web of Science ®Google Scholar
• Wickens S, Bowden SC, D’souza W. Cognitive functioning in children with self-limited epilepsy with centrotemporal spikes: a systematic review and meta-analysis. Epilepsia. 2017;58(10):1673–1685. doi:10.1111/epi.13865
   PubMed Web of Science ®Google Scholar
• Zanaboni MP, Pasca L, Bova SM, et al. WISC-IV intellectual profiles in Italian children with self-limited epilepsy with centrotemporal spikes. Epileptic Disord. 2023;25(2):160–172. doi:10.1002/epd2.20003
   Web of Science ®Google Scholar
• Moritz S, Conor G, Najma A, et al. Care and three-year outcomes of children with benign epilepsy with centro-temporal spikes in England. Epilepsy Behav. 2023;148:109465. doi:10.1016/j.yebeh.2023.109465
   Web of Science ®Google Scholar
• Operto FF, Pastorino GMG, Mazza R, et al. Cognitive profile in BECTS treated with levetiracetam: a 2-year follow-up. Epilepsy Behav. 2019;97:187–191. doi:10.1016/j.yebeh.2019.05.046
   Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308–1317. doi:10.1111/j.1528-1167.2007.01188.x
   PubMed Web of Science ®Google Scholar
• Curia G, Biagini G, Perucca E, Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555–568. doi:10.2165/00023210-200923070-00002
   PubMed Web of Science ®Google Scholar
• Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958–967. doi:10.1111/j.1528-1167.2009.02496.x
   PubMed Web of Science ®Google Scholar
• Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: effi cacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443–453. doi:10.1111/j.1528-1167.2008.01951.x
   PubMed Web of Science ®Google Scholar
• Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017;16(1):43–54. doi:10.1016/S1474-4422(16)30292-7
   PubMed Web of Science ®Google Scholar
• Roberti R, Di Gennaro G, Anzellotti F, et al. A real-world comparison among third-generation antiseizure medications: results from the COMPARE study. Epilepsia. 2023;65(2):456–472. doi:10.1111/epi.17843
   Web of Science ®Google Scholar
• Tohru O, Yuji F, Satoru S, et al. Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes. Brain Dev. 2022;44(6):380–385. doi:10.1016/j.braindev.2022.02.005
   Web of Science ®Google Scholar
• Zhao T, Li HJ, Ma L, et al. Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China. Epilepsy Behav. 2021;117:107814. doi:10.1016/j.yebeh.2021.107814
   Web of Science ®Google Scholar
• Yue L, Guo H-L, Zhang -Y-Y, et al. Plasma lacosamide monitoring in children with epilepsy: focus on reference therapeutic range and influencing factors. Front Pediatr. 2022;10. doi:10.3389/fped.2022.949783
   Web of Science ®Google Scholar
• Parisi P, Paolino MC, Raucci U, et al. Atypical forms of benign epilepsy with centrotemporal spikes (BECTS): how to diagnose and guide these children. A practical/scientific approach. Epilepsy Behav. 2017;6(75):165–169. doi:10.1016/j.yebeh.2017.08.001
   Google Scholar
• Liu N, Zhou T, Zhu JP, et al. Clinical feature and treatment strategy of benign childhood epilepsy with centrotemporal spikes. Chin Pediatr Emerg Med. 2017;24(3):228–232.
   Google Scholar
• European Medicines Agency. Lacosamide: summary of product characteristics [EB/OL].2022. Available from: https://www.ema.europa.eu/en/documents/product-information/vimpat-epar-product-information_en.pdf. Accessed February 28, 2024.
   Google Scholar
• US FDA. Vimpat(lacosamide): highlights of prescribing information [EB/OL]. 2021. Available from: https://www.vimpat.com/vimpat-prescribing-information.pdf. Accessed February 28, 2024.
   Google Scholar
• Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2010;13(1):21–42. doi:10.1111/j.1527-3458.2007.00001.x
   Google Scholar
• Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189–205. doi:10.1016/j.eplepsyres.2014.11.021
   PubMed Web of Science ®Google Scholar
• Farkas A, Steinborn B, Flamini JR, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal sei-zures. Neurology. 2019;93(12):e1212–e1226. doi:10.1212/WNL.0000000000008126
   Web of Science ®Google Scholar
• Meschede C, Witt JA, Rademacher M, et al. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure. 2018;58:141–146. doi:10.1016/j.seizure.2018.04.015
   PubMed Web of Science ®Google Scholar
• Biton V, Gil-nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav. 2015;52(Pt.A):119–127. doi:10.1016/j.yebeh.2015.09.006
   Google Scholar
• Hong Z, Inoue Y, Liao W, et al. Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study. Epilepsy Res. 2016;127:267–275. doi:10.1016/j.eplepsyres.2016.08.032
   PubMed Web of Science ®Google Scholar